Anteris Technologies Announces Private Placement
Anteris Technologies Global Corp. (AVR: ASX), a structural heart company, has announced a private placement to raise approximately A$38.5 million (US$25.2 million).
The funds will be raised through the issuance of 5,135,000 shares and CHESS Depositary Interests (CDIs) to design, develop, and commercialise cutting-edge medical devices.
The company's lead product, the DurAVR Transcatheter Heart Valve (THV), treats aortic stenosis.
- The placement comprises an offer of 2,346,936 new shares at US$4.90 per share, raising approximately US$11.5 million (A$17.6 million).
- Each share includes a warrant to acquire a share at US$7.50, expiring in five years.
- 2,788,064 new CDIs will be offered at A$7.
Anteris Technologies is committed to designing, developing, and commercialising cutting-edge medical devices to restore healthy heart function.
Author's summary: Anteris Technologies raises A$38.5 million in private placement.